Literature DB >> 16799883

Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.

Yosuke Kumekawa1, Kazuhiro Kaneko, Hiroaki Ito, Toshinori Kurahashi, Kazuo Konishi, Atsushi Katagiri, Taikan Yamamoto, Meiko Kuwahara, Yutaro Kubota, Takashi Muramoto, Yoshihide Mizutani, Michio Imawari.   

Abstract

BACKGROUND: We retrospectively investigated long-term toxicity after concurrent chemoradiotherapy (CRT) for patients with esophageal squamous cell carcinoma (ESCC).
METHODS: Concurrent chemoradiotherapy was performed in 110 patients with T1 to T4 disease containing M1 lymph node (LYM) disease. Chemotherapy consisted of protracted infusion of 5-fluorouracil 400 mg/m(2) per 24 h on days 1 to 5 and 8 to 12, combined with 2-h infusion of cisplatin 40 mg/m(2) on days 1 and 8. Radiation treatment of the mediastinum at a dose of 30 Gy in 15 fractions was administered concomitantly with chemotherapy. A course schedule with a 3-week treatment and a 2-week break was applied twice, with a total radiation dose of 60 Gy. For the assessment of toxicity, the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring schema was adopted.
RESULTS: A total of 81 patients were recruited in patients with stage I to IVA. Of 34 patients with complete response, 1 patient died as a result of acute myocardial infarction. Grade 2, 3, and 4 late toxicities occurred with the following incidences: pericarditis in 3 patients, 1 patient, and 2 patients, respectively; heart failure in 0, 0, and 3 patients; pleural effusion in 2, 3, and 0 patients; and radiation pneumonitis in 0, 0, and 1 patient, respectively.
CONCLUSIONS: Definitive chemoradiotherapy for ESCC is effective with substantial toxicities. Further investigation is warranted to minimize the normal tissue toxicities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799883     DOI: 10.1007/s00535-006-1771-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  28 in total

1.  Curative non-surgical combined treatment of squamous cell carcinoma of the oesophagus.

Authors:  T Zenone; P Romestaing; R Lambert; J P Gerard
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

2.  Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases.

Authors:  J P Veinot; W D Edwards
Journal:  Hum Pathol       Date:  1996-08       Impact factor: 3.466

3.  Comparison of CT and MR imaging in staging of neck metastases.

Authors:  H D Curtin; H Ishwaran; A A Mancuso; R W Dalley; D J Caudry; B J McNeil
Journal:  Radiology       Date:  1998-04       Impact factor: 11.105

4.  Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.

Authors:  A Ohtsu; N Boku; K Muro; K Chin; M Muto; S Yoshida; M Satake; S Ishikura; T Ogino; Y Miyata; S Seki; K Kaneko; A Nakamura
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Radiation-related chronic heart disease.

Authors:  K J Tötterman; E Pesonen; P Siltanen
Journal:  Chest       Date:  1983-06       Impact factor: 9.410

6.  Chemoradiotherapy of esophageal carcinoma.

Authors:  E A Poplin; P S Khanuja; M J Kraut; A M Herskovic; P B Lattin; G Cummings; L E Gaspar; J L Kinzie; Z Steiger; V K Vaitkevicius
Journal:  Cancer       Date:  1994-08-15       Impact factor: 6.860

7.  Carcinoma of the esophagus: CT vs MR imaging in determining resectability.

Authors:  S Takashima; N Takeuchi; H Shiozaki; K Kobayashi; S Morimoto; J Ikezoe; N Tomiyama; K Harada; K Shogen; T Kozuka
Journal:  AJR Am J Roentgenol       Date:  1991-02       Impact factor: 3.959

8.  Coronary artery disease mortality in patients treated for Hodgkin's disease.

Authors:  J F Boivin; G B Hutchison; J H Lubin; P Mauch
Journal:  Cancer       Date:  1992-03-01       Impact factor: 6.860

9.  Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.

Authors:  A A Forastiere; M B Orringer; C Perez-Tamayo; S G Urba; M Zahurak
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

10.  Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus.

Authors:  K Kaneko; H Ito; K Konishi; T Kurahashi; T Ito; A Katagiri; T Yamamoto; T Kitahara; Y Mizutani; A Ohtsu; K Mitamura
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more
  26 in total

1.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.

Authors:  Andre Konski; Tianyu Li; Michael Christensen; Jonathan D Cheng; Jian Q Yu; Kevin Crawford; Oleh Haluszka; Jeffrey Tokar; Walter Scott; Neal J Meropol; Steven J Cohen; Alan Maurer; Gary M Freedman
Journal:  Radiother Oncol       Date:  2012-06-07       Impact factor: 6.280

2.  Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue.

Authors:  Ichinosuke Hyodo
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

3.  Treatment with Corticosteroid for Pericardial Effusion in a Patient with Advanced Synchronous Esophageal and Gastric Cancers following Chemoradiotherapy.

Authors:  Satoshi Osawa; Takanori Yamada; Takeji Saitoh; Takashi Kosugi; Tomohiro Terai; Yasuhiro Takayanagi; Yasushi Hamaya; Ken Sugimoto; Mutsuhiro Ikuma
Journal:  Case Rep Gastroenterol       Date:  2010-07-24

4.  Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy.

Authors:  K Hayashi; Y Fujiwara; M Nomura; M Kamata; H Kojima; M Kohzai; K Sumita; N Tanigawa
Journal:  Br J Radiol       Date:  2014-11-27       Impact factor: 3.039

5.  Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer.

Authors:  Ichiro Ogino; Shigenobu Watanabe; Kentaro Sakamaki; Yuka Ogino; Chikara Kunisaki; Kazuo Kimura
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

Review 6.  Constrictive Pericarditis 5 Months after Radiation Therapy in a 62-Year-Old Woman with Esophageal Cancer.

Authors:  Beeletsega T Yeneneh; Sorcha Allen; Prasad Panse; Farouk Mookadam; William Rule
Journal:  Tex Heart Inst J       Date:  2017-12-19

7.  Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer.

Authors:  Liru He; Andrew Chapple; Zhongxing Liao; Ritsuko Komaki; Peter F Thall; Steven H Lin
Journal:  Radiother Oncol       Date:  2016-08-22       Impact factor: 6.280

8.  Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.

Authors:  Akiko Kuwahara; Motohiro Yamamori; Kohshi Nishiguchi; Tatsuya Okuno; Naoko Chayahara; Ikuya Miki; Takao Tamura; Kaori Kadoyama; Tsubasa Inokuma; Yoshiji Takemoto; Tsutomu Nakamura; Kazusaburo Kataoka; Toshiyuki Sakaeda
Journal:  Int J Med Sci       Date:  2010-01-31       Impact factor: 3.738

9.  Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Authors:  Akiko Kuwahara; Motohiro Yamamori; Kohshi Nishiguchi; Tatsuya Okuno; Naoko Chayahara; Ikuya Miki; Takao Tamura; Tsubasa Inokuma; Yoshiji Takemoto; Tsutomu Nakamura; Kazusaburo Kataoka; Toshiyuki Sakaeda
Journal:  Int J Med Sci       Date:  2009-09-28       Impact factor: 3.738

10.  Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.

Authors:  Satoshi Osawa; Takahisa Furuta; Ken Sugimoto; Takashi Kosugi; Tomohiro Terai; Mihoko Yamade; Yasuhiro Takayanagi; Masafumi Nishino; Yasushi Hamaya; Chise Kodaira; Takanori Yamada; Moriya Iwaizumi; Kosuke Takagaki; Ken-ichi Yoshida; Shigeru Kanaoka; Mutsuhiro Ikuma
Journal:  BMC Cancer       Date:  2009-11-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.